Results - Financial Results 2025
Awaiting price reaction for this filing.
Sarda Proteins Ltd (solar cell products / renewable energy segment) posted unaudited results for Q2 FY26 and H1 FY26. Revenue from operations surged to Rs. 1,536.46 lakhs in H1 FY26 from just Rs. 14 lakhs in H1 FY25, driven by Q2 sales of Rs. 430.38 lakhs and Q1 sales of Rs. 1,095.46 lakhs. Despite the sharp revenue jump, the company reported a net loss of Rs. 8.88 lakhs for the half year, as a Q1 loss of Rs. 49.34 lakhs outweighed a Q2 profit of Rs. 40.46 lakhs. Operating cash flow was deeply negative at Rs. (8,259.39) lakhs, while financing activities brought in Rs. 8,269.22 lakhs, mainly from share application money of Rs. 8,248.75 lakhs. Total assets expanded sharply to Rs. 8,712.54 lakhs from Rs. 264.80 lakhs, mostly in loans/advances and trade receivables. Statutory auditor A H Mandaliya & Associates issued an unmodified review report.
The dramatic revenue scaling is encouraging, but profitability and self-funded operations are weak — the business is essentially being financed by incoming share application money rather than internal cash generation. For shareholders, this raises concerns about earnings quality and sustainability despite the topline surge.